Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)
| dc.contributor.author | Buffels, R. | |
| dc.contributor.author | Comi, G. | |
| dc.contributor.author | Wiendl, H. | |
| dc.contributor.author | Kuhelj, R. | |
| dc.contributor.author | Wei, W. | |
| dc.contributor.author | Siva, A. | |
| dc.contributor.author | Vermersch, P. | |
| dc.contributor.author | Eralinna, J. -P. | |
| dc.contributor.author | Nicholas, R. | |
| dc.contributor.author | Oreja-Guevara, C. | |
| dc.contributor.author | Van Wijmeersch, B. | |
| dc.date.accessioned | 2021-03-04T14:37:29Z | |
| dc.date.available | 2021-03-04T14:37:29Z | |
| dc.identifier.citation | Vermersch P., Eralinna J. -. , Nicholas R., Oreja-Guevara C., Siva A., Van Wijmeersch B., Wiendl H., Buffels R., Kuhelj R., Wei W., et al., "Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)", 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.344-345 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_828302c2-4895-489b-bed6-8ee7e2fb8614 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/88896 | |
| dc.language.iso | eng | |
| dc.subject | Sinirbilim ve Davranış | |
| dc.subject | Yaşam Bilimleri (LIFE) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Nöroloji | |
| dc.subject | Yaşam Bilimleri | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Temel Bilimler | |
| dc.subject | NEUROSCIENCES | |
| dc.subject | Klinik Tıp | |
| dc.subject | KLİNİK NEUROLOJİ | |
| dc.title | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results) | |
| dc.type | Bildiri | |
| dc.contributor.department | İstanbul Üniversitesi , , | |
| dc.identifier.volume | 25 | |
| dc.contributor.firstauthorID | 156963 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Bildiri [64839]